cyrilzakka/clinical-trials huggingface dataset:
Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis

This is a study comparing the current standard of care surgical treatment to a newer surgical procedure involving the implantation of osteochondral allograft at the base of the thumb. Patients will be followed at 1, 3, 6 months and 1 year post-operatively.

Basal joint arthritis of the thumb is a common condition associated with considerable morbidity. Many non-operative and operative treatments have been described, but few multicenter prospective evidence based trials exist comparing standard treatments. This continuing search for consensus and improvement of best clinical practice has been reviewed in a thorough meta-analysis of operative treatments for basal joint arthritis. Operative treatments range from osteotomy, partial or complete trapeziectomy with or without reconstruction of the ligaments, tendon interposition to arthrodesis, however the functional outcome varies. Allograft has been previously described in joint replacement / prosthetic implantation surgery in other areas of the body, however not in the thumb. The purpose of this study is to investigate using osteochondral allograft in the surgical intervention phase of treatment for patients with basal joint arthritis.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Indicated for operative management of basal joint arthritis

Exclusion Criteria:

* Pregnant women/fetuses/neonates, prisoners
* Previously operated on for treatment of basal joint arthritis
The Effect of Three Different Dietary Messages on Dietary Intake and Health in Families

Examine the effect of three different dietary messages on dietary intake and the health of parents and their children.

The goal of this pilot study is to conduct a randomized controlled trial examining three dietary messages: increase fruits and vegetables \[INCREASE\], decrease energy-dense, non-nutrient dense snack foods \[DECREASE\], or increase fruits and vegetables plus decrease snack foods \[INCREASE+DECREASE\], within a 6-month, family-based obesity prevention intervention. Each condition will also focus on increasing family evening meals and physical activity. Primary hypotheses are: 1) INCREASE + DECREASE will consume a greater ratio of F\&Vs:SFs than INCREASE and DECREASE at 6 months.

2)INCREASE + DECREASE will consume less energy than INCREASE and DECREASE at 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Children between ages 6-12 years
* BMI percentile \> 5th and \< 85th percentile for age and sex
* Have a parent aged \> 21 years with a BMI \> 25
* Have an overweight/obese parent willing to attend intervention meetings
* Parent and child speak and read English
* Not moving out of the metropolitan area during the course of the investigation

Exclusion Criteria:

* Reporting that the child and parent planning to participate have dietary restrictions related to fruit and vegetable intake
* Physical activity restrictions
* A parent reporting that she is pregnant, planning to become pregnant, or currently breastfeeding
German National Registry for NSS

The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.

Today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard treatment for small renal masses according to international guidelines. Open PN ist still the predominant apporach in Germany, but the use of minimally-invasive surgery has continously increased over the last decades. Specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive PN approach even in more complex renal tumours. Real world data on the outcomes of PN according to the surgical approach are limited. Data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity.

The G-NESS registry database aims at prospectively collecting such clinical and outcome data from patients undergoing PN. Data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. Follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. The information received from the database can help to better define the optimal surgical care for patients with renal masses.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Written informed consent
* Localized renal parenchymal mass amenable to nephron-sparing surgery
* Adequate imaging of the abdomen (CT or MR with contrast)

Exclusion Criteria:

* Patient with (or suspected to have) urothelial cancer of the kidney
* Prior nephron-sparing surgery on ipsilateral kidney
* metastasized renal cell carcinoma
Treatment of Soft Tissue Loss With Nerve Defect in the Finger Using the Boomerang Nerve Flap

Soft tissue loss with proper digital nerve (PDN) defect in the finger results in sensory loss of the finger pulp. Reconstruction of these complex soft tissue defects continues to be a challenge problem. To resolve this problem, we combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas. For comparison, we also collected a consecutive series of 32 patients with similar injury in the finger treated using a cross finger flap and a secondary free nerve graft.

The patients in this study group were required to meet all of the following criteria: soft tissue loss between the midpoint of the distal phalanx and PIP joint; associated PDN defect 1 to 4 cm in length; single or double PDN defects; and simultaneous repair of soft tissue loss and PDN defect. Patients were excluded when they had the following: injury to the course of the vascular pedicle or the donor site or the donor nerve; PDN defect less than 1 cm or larger than 4 cm in length; direct PDN repair; and thumb neurocutaneous defects.

Eligibility Criteria:
Inclusion Criteria:

* soft tissue loss between the midpoint of the distal phalanx and PIP joint; - associated PDN defect 1 to 4 cm in length;
* single or double PDN defects;
* simultaneous repair of soft tissue loss and PDN defect.

Exclusion Criteria:

* injury to the course of the vascular pedicle or the donor nerve;
* PDN defect less than 1 cm or larger than 4 cm in length;
* direct PDN repair;
* thumb neurocutaneous defects.
Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

The purpose of this study is to examine the role of a well-known and well-tolerated antibiotic, doxycycline, in the treatment of cystic fibrosis patients who are hospitalized. This antibiotic does not effectively treat the bacteria in airways of cystic fibrosis patients, but may reduce the activity of inflammatory molecules in the disease.

One molecule that is inhibited by doxycycline is matrix metalloprotease-9, which is emerging as an important mediator of lung inflammation and damage in cystic fibrosis. We hypothesize that the addition of treatment with doxycycline in CF inpatients will reduce MMP-9 activity and inflammatory markers in the sputum of cystic fibrosis patients compared to CF patients not treated with doxycycline.

Eligibility Criteria:
Inclusion Criteria:

* Cystic Fibrosis
* Hospitalization for Pulmonary exacerbation

Exclusion Criteria:

* Significant GI illness
* Participation in another Investigational Protocol
* Allergies to Doxycycline
* Sputum Culture only positive for Staphylococcus aureus,
* Pregnant or Nursing
* Unwilling to use effective birth control
* Elevated LFT's greater than 3x the upper limit of normal
* Creatinine greater than 1.5x the upper limit of normal
* Lung transplantation
* Substance abuse within 30 days of screening
Skills-training for Reducing Risky Alcohol Use in App Form

This study evaluates the efficacy of a skills training web-based mobile phone application, Telecoach among individuals in the general population seeking help for their risky alcohol consumption on the Internet. The design is a two-armed randomized controlled design, and outcomes are measured in terms of changes in excessive alcohol use at follow up 6, 12 and 26 weeks after study initiation and baseline data gathering. The Telecoach web app delivers skills training in the form of exercises commonly used in psychosocial interventions for risky alcohol use. The controll condition is a web app providing information on the effects of alcohol on the consumers' health.

This study evaluates the efficacy of a skills training web-based mobile phone application, Telecoach among individuals in the general population seeking help for their risky alcohol consumption on the Internet. The design is a two-armed randomized controlled design, and outcomes are measured in terms of changes in excessive alcohol use at follow up 6, 12 and 26 weeks after study initiation and baseline data gathering.

Individuals seeking help for problematic alcohol use on the internet will get access to a webpage with information about the study. Individuals leaving informed consent are asked to fill out questionnaires about alcohol use, depression, anxiety and information on gender and weight. Those with excessive alcohol use (\>14 standard glasses/week for men and \> 9 for women) are randomized into one of two groups: 1. Access to the Telecoach web-app and 2. Access to a control condition with an information-providing web-app.

Outcomes on alcohol use are gathered by electronic self-registration at 6, 12 and 26 weeks after study initiation. Additional questions on the users' satisfaction with the app assigned to them and other support for problematic alcohol used during the research period at 26 weeks.

The Telecoach web-app is a skills-training app developed for use on a mobile smart-phone. The skills-training components are common to psychosocial treatment protocols for problematic alcohol consumption.

The control condition web-app is a simple text-based app providing information on the effects of alcohol on the consumers' health.

Outcomes will be reported, analyzed and discussed in a scientific article.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years
* Risky alcohol consumption defined as Alcohol Use Disorders Identification Test (AUDIT) scores of ≥6 points for women and ≥ 8 points for men.

Exclusion Criteria:

* Severe depression, defined as a MADRS-S score of \> 30
* Sucide risk, defined as a MADRS-S, item 9 (Lust for life) score \> 4
* Drug abuse, defined as a score of ≥ 8 on the DUDIT
Retail Outlet Health Kiosk Hypertension Trial

The investigators propose to conduct pilot studies to support an application to conduct a fully powered randomized trial of a text messaging intervention to increase the rate of blood pressure control, defined as \<140/90 mmHg, among hypertensive individuals using health kiosk blood pressure devices. These pilot studies will include testing of the intervention, recruitment, enrollment, and data collection procedures, and of the web-based interactions between the data coordinating center and higi Sh llc (Chicago, IL), which is the company that installs and maintains the health care kiosks and associated software infrastructure. Completion of these pilot studies will provide preliminary data to support an application for a full scale randomized controlled study. Potential for adaption is high because of alignment of retail outlets, kiosk providers, and consumers for health, wellness, and self-care.

Cardiovascular disease (CVD) remains the leading cause of death in the U.S. as well as the leading cause of health care cost. Hypertension is the leading remediable risk factor for CVD in the U.S. and globally, with prevalence of 29% in U.S. adults. Recent data from NHANES indicate that blood pressure (BP) is not controlled, defined as \<140/90 mmHg, in 48% of individuals in the U.S. with hypertension. Strategies to improve hypertension control have focused on the physician-patient interaction at the office visit, system factors in the health care provider system, and extension beyond the traditionally defined health care system. All have had some success but are limited by not reaching individuals outside the clinical encounter or by challenges of scale, scope, and standardization of blood pressure measurement outside the clinical setting. Retail outlet BP devices have the potential to address these limitations by providing free BP measurements to individuals outside the clinical setting and at all times the retail outlet is open. These automated devices are standardized and linked to software with the ability to collect data and provide information to individuals using these devices, thereby providing a platform for an intervention strategy. Higi is a privately owned company that provides health kiosks in retail outlets. Higi presently has 10,800 kiosks in the U.S. with 4,125 in Rite Aid pharmacies. More than 44 million BP measurements per year are obtained at higi kiosks. In the one-year period 7/1/15 to 6/30/16, approximately 727,000 individuals using higi kiosks recorded \>3 systolic BP measurements \>140/90 mmHg. The investigators propose to target this group using interactive text messaging to activate individuals to take actions to improve BP control. The primary endpoint will be BP control defined as \<140/90 mmHg at 12 months post randomization.

Eligibility Criteria:
Inclusion Criteria:

* \>3 systolic blood pressure measurements \>140/90 mmHg (two in the previous 12 months + one at baseline)
* Age 18-85 years
* Weight \<300 pounds
* Has a cell phone
* Can provide consent
* Speaks English or Spanish
Validation of the HAR Score for Prioritization of Patients Calling the Emergency Medical Service for Chest Pain by Emergency Call Dispatcher

The lifetime prevalence of chest pain in the general population is 20-40%. The etiologies to be evoked from the outset of management are those of cardiovascular origin, such as acute coronary syndrome (ACS) and pulmonary embolism. ACS is responsible for almost 20% of deaths. Delay in treatment is a major prognostic factor, given the importance of coronary reperfusion.

In France, one of the first contacts with the healthcare system is the medical regulation assistant (MRA) at the Centre 15. His or her role is to prioritize the call according to the identification of immediate signs of seriousness, and if necessary, to decide autonomously to send a rescue team before medical regulation. Depending on the reason for the call and any signs of seriousness, it prioritizes the call according to the expected response time. In line with current recommendations, all calls for chest pain should be answered by an emergency medical dispatcher (EMR) within 5 minutes. However, 60-90% of chest pain calls are not of cardiovascular origin. Their prioritization could therefore be re-qualified for longer response times.

Given the frequency of this type of call, a more efficient MRA referral strategy is needed. To achieve this, decision-support tools would be essential.

The performance of the HAR (History, Age and Risk Factors) score has been recently explored, derived from the HEART score, in a previous single-center prospective study in 2019. It stratifies the risk of a major cardiovascular event (MCE) into low (0 or 1 point), intermediate (2 or 3 points) or high (4, 5 or 6 points).

Investigator's hypothesis is that the HAR score could be entrusted to MRA, to enable them to optimize the prioritization of patients calling with non-traumatic chest pain, by qualifying low-risk chest pain calls on the one hand, which could be prioritized in P2 SNP, and high-risk calls on the other, making it possible to anticipate the dispatch of an emergency service.


Eligibility Criteria:
Inclusion Criteria:

* Patient of legal age (≥ 18 years)
* Calling Center 15 from 49, 72 or 37
* Expressing non-traumatic chest pain, even if this is not the main reason for seeking help.

Exclusion Criteria:

* Treatment in departments other than 49, 72 and 37
* Taken in charge in an emergency department of a private facility in the 49, 72 and 37 départements
* Poor understanding of the French language
* Non-affiliated or non-beneficiary of a social security scheme
* Person deprived of liberty by judicial or administrative decision
* Person under forced psychiatric care
* Person subject to a legal protection measure
* Person unable to express his/her non-opposition.
* Follow-up at Day 30 impossible for any reason
* Person having expressed his/her opposition to the collection of his/her data.
Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

Lower urinary tract symptoms such as urinary leakage and overactive bladder affect millions of American women. Women may develop these problems because the innervation of the muscles of the bladder and urethra are injured. Most research on treating these problems has focused on the abnormalities of the bladder muscle, but newer studies have shown abnormalities in the innervation and muscle function of the urethra.

Women with these symptoms may benefit from treatment with medications to improve their urethral function. However, to truly understand what types of medications will help women with these symptoms, the investigators wish to study how these medications affect innervation and muscle function in healthy women who do not have lower urinary tract symptoms.

Women without urinary incontinence or bladder symptoms (healthy controls)will undergo urethral testing prior to randomization to one of 5 medications or placebo. Participants will take an oral medication for 2 weeks and then return for repeat testing.

Eligibility Criteria:
Inclusion Criteria:

* Healthy Females only
* Ages 19-51 and up including pre-menopausal older women who have had a normal menstrual cycle for the prior 3 months
* Able to take oral medication for 2 weeks
* For women of child bearing potential,willing to use an approved method of birth control during the study

Exclusion Criteria:

* Urinary Incontinence or other bladder symptoms
* Known neurologic disease that may impair urethral tone or sensation
* Currently taking a class of medication that is being tested (alpha-antagonists, anticholinergics, sympathomimetics, tricyclic antidepressants, or skeletal muscle relaxants)
* History of QTc prolongation or cardiac arrhythmia
* Pregnant, breastfeeding, or are less than 6 months postpartum
* Known hypersensitivity to or other contraindications to taking any of the study medications
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.


Eligibility Criteria:
Inclusion Criteria:

* Locally advanced or MBC with progression after at least one chemotherapeutic regimen for advanced disease eligible for treatment with eribulin according to Fachinformation. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless participants were not suitable for these treatments
* 1-3 prior chemotherapeutic regimens for advanced disease
* Age \>=18 years at the time of Informed Consent
* Ability to understand and willingness to respond to questions related to their health
* Decision for the participant to start treatment with eribulin has been made prior to inclusion in this study.
* Signed written Informed Consent

Exclusion Criteria:

* Previous treatment with eribulin in any line of treatment
* Contraindication according to the Fachinformation of eribulin
* Pregnancy or lactation
* Participation in an interventional clinical trial at the same time
The Effect of Botulinum Toxin Injection at Hip Adductor Muscles in Patients With Spastic Cerebral Palsy, Pilot Study

In children with cerebral palsy, secondary problems lead to hip dislocation. the purpose of this study is to find out the effects of botulinum toxin A on hip joint dislocation in cerebral palsy patients.

* Design: Prospective study
* Inclusion criteria of patient group: who has a cerebral palsy and GMFCS level 3,4,5
* Intervention: applied medication Botulinum A injection (meditox 200unit)
* Main outcome measures: The investigators will measure for finding evidence by checking the x-ray photograph, hip adductor and muscles pressure test and electromyography(EMG test) test of hip adductor, abductor and spine muscles.

Eligibility Criteria:
Inclusion Criteria:

* Severe cerebral palsy patients(GMFCS level 3,4,5)
* 2 to 10 years old

Exclusion Criteria:

* Those who disagree with the study.
* other than cerebral palsy.
Advancing Prevention of Pulmonary Fibrosis

This study plans to learn more about pulmonary fibrosis and how it develops. We want to determine if the disease can be detected early, before the lung is permanently scarred.

This study will enroll participants who are not currently diagnosed with pulmonary fibrosis, but who have family members with pulmonary fibrosis. Because there is an increased risk within affected families, this cohort will allow us to learn how pulmonary fibrosis develops, and how the lungs change over time.


Eligibility Criteria:
Inclusion Criteria:

* Unaffected first degree relative from Familial Interstitial Pneumonia families (two or more family members with IIP)
* Age at least 40 years old and younger than 75 years old

Exclusion Criteria:

* Diagnosed with known (physician-diagnosed) pulmonary fibrosis prior to informed consent
* Other genetic diseases associated with interstitial lung disease
* Pregnant women
Desarda's Technique Versus Lichtenstein's Technique Hernia Repair in Management of Elective Non-Complicated Inguinal Hernia

This study aims to compare Desarda's technique and Lichtenstein's technique of hernia repair in managing elective, non-complicated inguinal hernia.

Mesh prosthesis was introduced to hernial surgery as a magic solution for any inguinal hernia, and it has significant advantages (Simplicity of the procedure, Mesh is cheap, and has a low recurrence rate). Still, mesh induces fibrosis that can lead to stiffness and foreign body sensation, which become a source of agony for the patient. Mesh infection is one of the serious complications that can lead to the removal of the mesh and long-term terms morbidity from Lichtenstein hernia repairs, such as Vas entrapment and Chronic groin pain.

Desarda technique requires no extensive dissection or only suturing; no mesh is needed, and it is easy to learn. It is still ferrated and determined the optimum procedure to treat an inguinal hernia. It is a straightforward operation that avoids the risks of mesh implantation, has a low recurrence rate, and can be done by non-consultant staff.

Eligibility Criteria:
Inclusion Criteria:

* Above 14 years of age.
* With reducible non-complicated inguinal or inguinoscrotal hernia; unilateral or bilateral

Exclusion Criteria:

* Obstructive uropathy or chronic obstructive pulmonary disease because they are contraindications to elective hernia surgery. They are associated with definite poor outcomes, such as high recurrence rates.
* Unfit patients for surgery
* Patients with strangulated hernia.
* Recurrent Hernias.
* Per operative finding of separated, thin, and/or weak external oblique aponeurosis